General Statement of Disclosure:

CONSULTING FEES/HONORARIA: CSL Behring(MODEST), AstraZeneca(MODEST), Omthera(MODEST), Boehringer Ingelheim(MODEST), Roche(MODEST), Takeda(MODEST), Merck Schering-Plough(MODEST), Sanofi-Regeneron(MODEST), Amgen Inc.(MODEST), Cerenis(MODEST), Eli Lilly and Company(MODEST), Novo Nordisk Inc.(MODEST), Pfizer(MODEST), Resverlogix(MODEST), CSL Sequiris(NONE) RESEARCH/RESEARCH GRANTS: Cerenis(SIGNIFICANT), Atheronova(SIGNIFICANT), AstraZeneca(SIGNIFICANT), Amgen(SIGNIFICANT), Novartis(SIGNIFICANT), Resverlogix(SIGNIFICANT), Eli Lilly(SIGNIFICANT), InfraReDx(SIGNIFICANT), Sanofi-Regeneron(SIGNIFICANT), Vaxxinity(SIGNIFICANT)

View Full Disclosure